Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
|Articles|June 28, 2022
Daily OTC Pearl: Nerve Pain Organic Plant Medicine
Author(s)Saro Arakelians, PharmD
Dual action for neuropathy and neuralgia pain relief as well as for use in diabetes-related nerve pain and shingles.
Advertisement
OTC/Lifestyle Pearl of the Day: Nerve Pain Organic Plant Medicine
Indication: Dual action for neuropathy and neuralgia pain relief as well as for use in diabetes-related nerve pain and shingles.
Insight:
- Shake well before use.
- Roll the product over the affected area 3 to 4 times daily.
- Keep stored in a dark place.
Source:
Advertisement
Related to this article
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Renal benefit appeared only in patients with albuminuria in a 75,455-person BMJ analysis, whereas sulfonylureas signaled faster decline without it.
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
4
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
5